Resumen de: EP4541266A1
A blood glucose measurement device according to an embodiment of the present invention comprises: a measurement unit that is partially inserted into the body of a subject and generates a blood glucose measurement signal by measuring a blood glucose concentration of the subject; a control unit that generates blood glucose measurement data by converting the blood glucose measurement signal into digital data; a storage unit that includes a plurality of storage areas and stores the blood glucose measurement data in the plurality of storage areas; and a communication unit that transmits the blood glucose measurement data stored in at least one of the plurality of storage areas to an external device, wherein the control unit determines the validity of the blood glucose measurement data stored in the plurality of storage areas, and controls the communication unit to transmit the blood glucose measurement data stored in at least one of the plurality of storage areas to the external device, based on a result of the determination.
Resumen de: EP4542574A2
Systems and methods for processing, transmitting and displaying data received from an analyte sensor, such as a glucose sensor, are disclosed. In an embodiment, a method for transmitting data between a first communication device associated with an analyte sensor and a second communication device configured to provide user access to sensor-related information comprises: activating a transceiver of a first communication device associated with an analyte sensor at a first time; and establishing a two-way communication channel with the second communication device; wherein the activating comprises waking the transceiver from a low power sleep mode using a forced wakeup from the second communication device.
Resumen de: EP4541390A2
The disclosed embodiments are directed to a wearable automatic drug delivery device configured to provide basal dosing of GLP-1 or co-formulation of GLP-1 and insulin. The size and frequency of the basal doses may be controlled by a medication delivery algorithm resident on the wearable drug delivery device based on a basal dosing history and readings from a continuous glucose monitor monitoring the glucose levels of the wearer of the device.
Nº publicación: EP4542560A1 23/04/2025
Solicitante:
INSULET CORP [US]
Insulet Corporation
Resumen de: EP4542560A1
Disclosed are methods, techniques, systems, and devices that are operable to compensate for the effects of pharmaceuticals on a user's analyte measurement values, such as glucose levels and/or ketone levels. The disclosed system is configured to enable medicament delivery application to enter a pharmaceutical mode. While in pharmaceutical mode, the medicament delivery application is operable to adjust medicament delivery constraints and other settings used by the medicament delivery application to respond to the effects of the pharmaceutical on the user's analyte measurement values.